home / lobbying

lobbying_activities

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

1,238 rows where filing_year = 2019 and issue_code = "PHA" sorted by filing_year descending

✎ View and edit SQL

This data as json, CSV (advanced)

Suggested facets: filing_type, is_termination, received_date (date)

filing_period 4

  • third_quarter 319
  • first_quarter 313
  • second_quarter 305
  • fourth_quarter 301

issue_code 1

  • PHA · 1,238 ✖

filing_year 1

  • 2019 · 1,238 ✖
id filing_uuid filing_type registrant_name registrant_id client_name filing_year ▲ filing_period issue_code specific_issues government_entities income_amount expense_amount is_no_activity is_termination received_date
2260471 PENN AVENUE PARTNERS d825b8cf-4fed-42a9-9ad0-648b0183f837 1T PENN AVENUE PARTNERS 400918672 PURDUE PHARMA L.P. 2019 first_quarter PHA Monitoring legislative and regulatory activities impacting the pharmaceutical industry.   20000   0 1 2019-01-16T17:34:48.747000-05:00
2260689 ML STRATEGIES, LLC 43b73cd0-67f9-42d9-90c7-da39d34987f9 1T ML STRATEGIES, LLC 25603 THE CAMPAIGN FOR SUSTAINABLE RX PRICING 2019 first_quarter PHA Issues related to prescription drug pricing Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 20000   0 1 2019-03-15T14:42:25.797000-04:00
2260783 NATIONAL RURAL HEALTH ASSOCATION df3ef15d-ae63-4f4e-9752-24473b91d23a Q1 NATIONAL RURAL HEALTH ASSOCATION 53048 NATIONAL RURAL HEALTH ASSOCATION 2019 first_quarter PHA The 340B Program and drug pricing Agriculture, Dept of (USDA),HOUSE OF REPRESENTATIVES,SENATE   16182 0 0 2019-03-27T12:59:52.753000-04:00
2260827 REPUBLIC CONSULTING, LLC aeb33366-a4de-4c70-9877-d780ea2a8637 Q1 REPUBLIC CONSULTING, LLC 401016871 IQVIA 2019 first_quarter PHA Monitor Data and Science Policy. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2019-03-30T12:58:06.777000-04:00
2261254 THE KUTLER GROUP e6c9c6c9-f1f8-4870-aafc-e04f3a1ef809 Q1 THE KUTLER GROUP 401103966 PRIME THERAPEUTICS 2019 first_quarter PHA drug pricing issues HOUSE OF REPRESENTATIVES,SENATE 24000   0 0 2019-04-02T15:33:16.990000-04:00
2261668 PENN AVENUE PARTNERS a32dcc98-e600-4ac4-95b7-106b6175e9aa Q1 PENN AVENUE PARTNERS 400918672 ALKERMES, INC. 2019 first_quarter PHA Regulatory and legislative issues impacting Alkermes. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2019-04-04T11:04:44.667000-04:00
2261759 AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION ed38ec67-d7b7-4760-be8c-ebad0321dd6e Q1 AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION 401103437 AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION 2019 first_quarter PHA Compounding Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA)     0 0 2019-04-04T14:11:45.137000-04:00
2261847 RED+BLUE STRATEGIES 597081be-a5cb-4d15-9286-5b161fa56365 Q1 RED+BLUE STRATEGIES 400693064 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) 2019 first_quarter PHA CREATES Act (S.340/ H.R. 965) - Issues related to reducing prices and increasing competition in the prescription drug marketplace. C-THRU Act (S. 476) - Issues related to transparency in the PBM space and ensuring that tools to decrease the cost of prescription medications are maintained. HHS rules and regulations related to the cost of prescription drugs, including, but not limited to, limiting rebates in the Medicare and Medicaid prescription drug benefits. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2019-04-04T15:25:32.360000-04:00
2261870 MCDERMOTT WILL & SCHULTE LLP 155d27a2-111e-428c-837a-1031a83f87c7 Q1 MCDERMOTT WILL & SCHULTE LLP 24338 MAXOR NATIONAL PHARMACY SERVICES, LLC 2019 first_quarter PHA Efforts to monitor and address pharmacy and drug pricing-related legislative and regulatory proposals, including, but not limited to, the 340B Program. HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA) 30000   0 0 2019-04-04T15:40:40.693000-04:00
2261893 NATIONAL RURAL HEALTH ASSOCATION 488dffff-72c2-4c09-bf6e-2d57b7ae675a 1A NATIONAL RURAL HEALTH ASSOCATION 53048 NATIONAL RURAL HEALTH ASSOCATION 2019 first_quarter PHA The 340B Program and drug pricing Agriculture, Dept of (USDA),HOUSE OF REPRESENTATIVES,SENATE   16182 0 0 2019-04-04T15:59:50.123000-04:00
2261902 RED+BLUE STRATEGIES 7c6b82f0-05e1-4d0b-8129-a172937a4967 Q1 RED+BLUE STRATEGIES 400693064 PEW CHARITABLE TRUSTS 2019 first_quarter PHA Issues related to the modernization of OTC monograph reform. Issues related to the implementation on the SUPPORT Act (P.L. 115-271) regarding MAT treatment. Issues related to curbing antibiotic resistance. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2019-04-04T16:07:52.587000-04:00
2262171 MS. TAMI WAHL 78aefeed-3ffc-41d1-a17e-e88ad872e04a 1T MS. TAMI WAHL 401104405 ROCK & ASSOCIATES 2019 first_quarter PHA Legislation impacting the operation of pharmacy compounding, and access to compounded medications. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 15000   0 1 2019-04-05T15:41:55.187000-04:00
2262178 MS. TAMI WAHL b3d56d01-29ca-477c-abae-0088c213da0e 1T MS. TAMI WAHL 401104405 ROCK & ASSOCIATES ON BEHALF OF PARRY, ROMANI, DECONCINI & SYMMS 2019 first_quarter PHA Working to ensure the implementation of the Drug Quality and Security Act (DQSA) (Food, Drug, and Cosmetic Act (503B)) is in alignment with the statutory language. Legislative efforts include working on draft guidance documents issued by FDA. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),SENATE,White House Office     0 1 2019-04-05T16:10:58.910000-04:00
2262434 COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE c0e27650-deaf-46d5-b803-82fb10537e71 Q1 COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE 11003 COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE 2019 first_quarter PHA CCAGW and NTU Urge Representatives to Oppose H.R. 107 CCAGW Offers Perspective on Medicare Drug Pricing Hearing CCAGW Offers Perspective on Medicare Drug Pricing Hearing CCAGW and NTU Urge Senators to Oppose H.R. 107 HOUSE OF REPRESENTATIVES,SENATE   30000 0 0 2019-04-08T11:04:33.497000-04:00
2262470 ACG ADVOCACY 9c68712d-07e8-4d06-a44d-b124585ccf58 Q1 ACG ADVOCACY 2057 WALGREEN CO. 2019 first_quarter PHA Competition Policy Issues. Drug Pricing Policy Issues. Data privacy and DIR fee reform. HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2019-04-08T12:09:56.253000-04:00
2262756 AMERICAN COLLEGE OF CLINICAL PHARMACY d34f67f2-7da7-455b-b142-9f4b17f1ca1e Q1 AMERICAN COLLEGE OF CLINICAL PHARMACY 57258 AMERICAN COLLEGE OF CLINICAL PHARMACY 2019 first_quarter PHA Coverage for direct patient care services of qualified clinical pharmacists under Medicare and other public health programs. Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE   144981 0 0 2019-04-09T09:12:15.970000-04:00
2262853 MCDERMOTT+ LLC 77fec801-6297-4042-93ce-b149cb7ab488 Q1 MCDERMOTT+ LLC 401103287 ALLIANCE FOR RURAL HOSPITAL ACCESS 2019 first_quarter PHA Amendments to Section 340B of the Public Health Service Act regarding eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2019-04-09T12:00:07.900000-04:00
2262887 UC HEALTH 35077f33-fe7b-4a20-b0a0-080de7851d81 Q1 UC HEALTH 401103195 UC HEALTH 2019 first_quarter PHA 340B, drug prices Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE     0 0 2019-04-09T13:02:53.750000-04:00
2262983 RED+BLUE STRATEGIES 7c42866b-64ea-4ed3-8f55-3628e709489f Q1 RED+BLUE STRATEGIES 400693064 COHERUS BIOSCIENCES 2019 first_quarter PHA Issues related to improving and expanding the biosimilars marketplace through policies that will create a more even playing field for biosimilars in the overall prescription drug marketplace in the United States. Areas of focus include policies regarding patent law, public and private reimbursement and FDA interchangeability standards. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2019-04-09T14:59:00.710000-04:00
2262998 RED+BLUE STRATEGIES c2765d73-375c-42be-abd5-fb8b7fb503d7 Q1 RED+BLUE STRATEGIES 400693064 CIGNA CORPORATION 2019 first_quarter PHA Issues related to Trump Administration proposals and regulations regarding drug pricing reforms, regulations regarding rebates, and related guidances focused on affordability and accessibility to prescription medications in the United States. Proposals, guidances and call letters and impacting Medicare Part D and the role of Pharmacy Benefit Managers. Issues related to transparency in the prescription drug marketplaces including new technologies to improve physician and patient access to real time pricing questions and concerns. Issues related to utilization and access to e- prescribing tools. Issues focused on the promotion of fair competition in the prescription drug market place, including policies focused on patents, biosimilars and generic medications. SENATE 60000   0 0 2019-04-09T15:17:20.657000-04:00
2263102 HOLLAND & KNIGHT LLP dfb26111-7424-4cd7-9132-928b9dbdab6e Q1 HOLLAND & KNIGHT LLP 18466 TEVA PHARMACEUTICALS USA, INC. 2019 first_quarter PHA Drug pricing. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2019-04-09T16:16:30.183000-04:00
2263259 RUBICON ADVISORS, LLC 1d439711-9207-420d-9077-68ddf0bd49fc Q1 RUBICON ADVISORS, LLC 315091 DYNAVAX TECHNOLOGIES 2019 first_quarter PHA Prescription Drug User Fee HOUSE OF REPRESENTATIVES,SENATE 45000   0 0 2019-04-10T08:32:20.017000-04:00
2263260 RUBICON ADVISORS, LLC da57a9f4-74fd-4266-83b9-e55a580f32f8 Q1 RUBICON ADVISORS, LLC 315091 DR. REDDY'S LABORATORIES, LTD 2019 first_quarter PHA Prescription Drug User Fee (PDUFA) re authorization.Generic Drug User Fee Act (GDUFA) re authorization. Border Adjustment Tax(BAT)issues Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 45000   0 0 2019-04-10T08:45:21.003000-04:00
2263262 RUBICON ADVISORS, LLC 3bc206cc-369c-4322-adda-d751837d6da7 Q1 RUBICON ADVISORS, LLC 315091 CONSCIOUS DISCIPLINE 2019 first_quarter PHA Medicare HOUSE OF REPRESENTATIVES,SENATE 37500   0 0 2019-04-10T08:51:23.010000-04:00
2263264 RUBICON ADVISORS, LLC 698a4230-c4fe-4792-a588-f9abdab53985 1T RUBICON ADVISORS, LLC 315091 LANNETT COMPANY, INC 2019 first_quarter PHA Medicare and Medicaid, Generic Prescription HOUSE OF REPRESENTATIVES,SENATE 45000   0 1 2019-04-10T08:57:25.017000-04:00
2263323 OLSSON, FRANK, WEEDA, TERMAN & MATZ, PC cec0d74a-970d-44ae-983f-dab1951fb238 Q1 OLSSON, FRANK, WEEDA, TERMAN & MATZ, PC 30212 NATIONAL ASSOCIATION OF CHAIN DRUG STORES 2019 first_quarter PHA Drug pricing, Direct and Indirect remuneration fees, Medicare Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2019-04-10T10:01:13.990000-04:00
2263356 NOVO NORDISK INC. 3efbb531-3d8c-45d3-8d75-1f6bd87ff22a Q1 NOVO NORDISK INC. 284790 NOVO NORDISK INC. 2019 first_quarter PHA H.R. 1520 Purple Book Continuity Act of 2019; H.R. 1503 Orange Book Transparency Act of 2019; issues related to importation; issues related to 340B Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   440000 0 0 2019-04-10T10:36:37.830000-04:00
2263593 LINCOLN PARK GROUP L.L.C. a5cce892-4114-406e-9dde-1399d9116295 Q1 LINCOLN PARK GROUP L.L.C. 401104374 CANADIAN INTERNATIONAL PHARMACY ASSOCIATION 2019 first_quarter PHA Support for S. 97/HR 447 Affordable and Safe Prescription Drug Importation Act and S. 61/HR 447 Safe and Affordable Drugs from Canada Act; issues related to personal drug importation. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2019-04-10T15:27:48.420000-04:00
2263614 KATE MOSS 964c82f9-219c-40d4-9bfd-7189e3144079 Q1 KATE MOSS 25988 CVS HEALTH 2019 first_quarter PHA Legislation impacting pharmacy benefit managers. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2019-04-10T15:49:05.760000-04:00
2263671 SIMS STRATEGIES, LLC d7c20d7a-cd26-4f41-84b5-785f5a943470 Q1 SIMS STRATEGIES, LLC 401104546 GLAXOSMITHKLINE, INC. 2019 first_quarter PHA Education and importance of various pharmaceutical industry issues, including issues affecting vaccines and shortages. SENATE 40000   0 0 2019-04-10T16:49:33.343000-04:00
2263733 BROYDRICK & ASSOCIATES caa0c200-1579-4860-99ac-1f9d91497b7e Q1 BROYDRICK & ASSOCIATES 7268 EXELA PHARMA SCIENCES 2019 first_quarter PHA Drug shortages and FDA approval. USTR acceptance. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2019-04-10T21:35:22.957000-04:00
2263748 BROYDRICK & ASSOCIATES 3f9413c3-a77f-41d7-90a0-3d13238c89bd Q1 BROYDRICK & ASSOCIATES 7268 TONIX PHARMACEUTICALS 2019 first_quarter PHA Funding new drug for PTSD. Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2019-04-10T21:48:34.083000-04:00
2263817 NVG, LLC 84349501-3b69-4172-9d8e-2a24b10cf504 Q1 NVG, LLC 76833 MANATT, PHELPS AND PHILLIPS, LLP (ON BEHALF OF NEKTAR THERAPEUTICS) 2019 first_quarter PHA FDA oversight of certain pain reliever products. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2019-04-11T09:56:29.080000-04:00
2263974 4C COMMUNICATIONS, INC. f4973b9b-3358-4b68-b7c2-8cf4e92e1173 Q1 4C COMMUNICATIONS, INC. 323717 HEALTHCARE LEADERSHIP COUNCIL 2019 first_quarter PHA Discussion on pharmaceutical drug pricing HOUSE OF REPRESENTATIVES,SENATE     0 0 2019-04-11T11:57:04.343000-04:00
2263996 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 84a0ffb0-8534-4e3a-bdf9-b641f68a4e79 Q1 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 AMERICAN SOCIETY OF HEMATOLOGY 2019 first_quarter PHA HR 1409, Cancer Drug Coverage Parity Act Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 30000   0 0 2019-04-11T12:11:13.627000-04:00
2264007 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 9fcd6c67-988e-46d5-9ad7-283a4d857f7f Q1 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 THE HEMOPHILIA ALLIANCE 2019 first_quarter PHA Issues related to the 340B drug discount program and drug pricing policies Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2019-04-11T12:15:16.977000-04:00
2264016 THORSEN FRENCH ADVOCACY LLC 150c8623-2d55-4aa0-9aa0-896d5479391b Q1 THORSEN FRENCH ADVOCACY LLC 400599826 HEALTHCARE DISTRIBUTION ALLIANCE 2019 first_quarter PHA General issues related to prescription drug abuse. Issues related to pharmaceutical market value. Prescription drug importation. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2019-04-11T12:17:21.120000-04:00
2264024 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. d9c94825-b406-4525-b6e3-e47580042fa7 Q1 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 NATIONAL ASSOCIATION OF EPILEPSY CENTERS 2019 first_quarter PHA Issues related to anti-epileptic drugs. Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 10000   0 0 2019-04-11T12:21:24.703000-04:00
2264069 THORSEN FRENCH ADVOCACY LLC bdc5ed90-32ef-4a1b-8713-9c22bc9d8d25 Q1 THORSEN FRENCH ADVOCACY LLC 400599826 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA 2019 first_quarter PHA Issues related to pharmaceutical market value. H.R.965/S.340: CREATES Act of 2019. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2019-04-11T12:47:40.597000-04:00
2264246 JOHNSON MATTHEY INC. f83bf0bd-928d-4e49-927b-e05121aee3ed Q1 JOHNSON MATTHEY INC. 401104441 JOHNSON MATTHEY INC. 2019 first_quarter PHA H.R. 965 and S. 340 CREATES Act of 2019, including provisions related to improving the process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market. H.R. 938 BLOCKING Act of 2019, including provisions related to discouraging parking of the 180-day exclusivity period for first generic companies challenging pharmaceutical patents. H.R. 990 and S. 344 Hatch-Waxman Integrity Act of 2019, including provisions relating to limit generic companies' ability to initiate inter partes review. H.R. 1520 Purple Book Continuity Act, including provisions relating to codifying publication of patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book. H.R. 1503 Orange Book Transparency Act, including provisions relating to requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 Protecting Consumer Access to Generic Drugs Act, including provisions relating to the prohibition of agreements between brand drug and generic manufacturers that pay generic manufacturers to keep the generic equivalent off the market. H.R. 1781 Payment Commission Data, including provisions relating to providing drug pricing and rebate data access the Medicare Payment Advisory Commission and Medicaid and CHIP Payment and Access Commission to help these commissions better understand the true costs of prescription drugs to consumers and taxpayers. Commerce, Dept of (DOC),Environmental Protection Agency (EPA),Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE   50000 0 0 2019-04-11T15:28:59.737000-04:00
2264510 CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER ed4c2a27-d660-4889-94da-cc9bed4acc76 Q1 CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 312496 CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 2019 first_quarter PHA Drug pricing, PCORI re-authorization Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,White House Office   40568 0 0 2019-04-12T10:03:07.977000-04:00
2264875 60 PLUS ASSOCIATION 9e596569-74d8-4933-9fea-a300b671bb52 Q1 60 PLUS ASSOCIATION 41988 60 PLUS ASSOCIATION 2019 first_quarter PHA Support affordable drug pricing, 349 B. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,White House Office     0 0 2019-04-12T14:45:35.763000-04:00
2265033 340B HEALTH d07d873e-677a-445a-86f2-9c1d14b69795 Q1 340B HEALTH 316434 340B HEALTH 2019 first_quarter PHA The 340B Drug Pricing Program; FY 2020 L-HHS Appropriations; final rules regarding 340B ceiling price calculations and manufacturer civil monetary penalties. Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE   274078 0 0 2019-04-12T17:31:48.787000-04:00
2265096 KEEFE STRATEGIES LLC (FKA KEEFE SINGISER PARTNERS) 193b386d-cf04-4ac6-9717-8e2ce2884e95 Q1 KEEFE STRATEGIES LLC (FKA KEEFE SINGISER PARTNERS) 401105192 CVS HEALTH 2019 first_quarter PHA Issues encompassing general education regarding the pharmacy benefit manager/pharmacy industry. Issues related to access and affordability of health care. Issues related to the proposed CVS-Aetna merger. HOUSE OF REPRESENTATIVES 15000   0 0 2019-04-13T06:44:22.317000-04:00
2265202 FLYNN & ASSOCIATES, INC. f62b4abe-ec14-44f1-b1d8-52b07dffc287 Q1 FLYNN & ASSOCIATES, INC. 15020 PHARMACEUTICAL INDUSTRY LABOR-MANAGEMENT ASSOCIATION 2019 first_quarter PHA HR. 1344 Competitive DRUGS Act of 2019 HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2019-04-14T15:26:52.517000-04:00
2265270 CHATMAN, LLC f02bf2bf-09c4-4fb8-bcc3-07e31a7bfead Q1 CHATMAN, LLC 400678024 LIVINGSTON GROUP FOR RUSH UNIVERSITY MEDICAL CENTER 2019 first_quarter PHA Maintain the 340B program for hospitals Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2019-04-14T21:54:28.257000-04:00
2265293 ACG ADVOCACY 67d9c312-f43e-44cd-b207-78c2bcc9d78c Q1 ACG ADVOCACY 2057 NATIONAL ASSOCIATION OF CHAIN DRUG STORES 2019 first_quarter PHA Advocacy on Medicare and Medicaid pharmacy coverage and reimbursement issues. Advocating for coverage of pharmacists services under Medicare Part B. Advocating for the passage of legislation that curbs prescription drug abuse while protecting patient access to medication. Advocating for fair and accurate Medicaid pharmacy reimbursement. Advocating for Medicare Part D changes that increase beneficiary eligibility for medication therapy management. Issues related to pharmacy reimbursement for 21st Century Cures. Issues regarding TriCare coverage for pharmacies. Issues regarding direct and indirect renumeration under Medicare Part D plans. Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2019-04-15T08:11:40.803000-04:00
2265418 TAUZIN STRATEGIC NETWORKS 2e205a4e-2dee-4c6a-8397-756ed17fe231 Q1 TAUZIN STRATEGIC NETWORKS 400786367 CAPTURERX 2019 first_quarter PHA Issues related to the 340b program HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2019-04-15T10:11:33.110000-04:00
2265733 PUBLIC CITIZEN d3d83d14-cdd9-4712-80f8-27054c0369c2 Q1 PUBLIC CITIZEN 32362 PUBLIC CITIZEN 2019 first_quarter PHA HR 1046/S 377-Medicare Negotiation and Competitive Licensing Act, Drug Pricing, HR 965-CREATES Act, Medicare for all Act, S 378/HR 1093-Stop price gouging Act, HR 985-Fast Generics act, HR 1499-Protecting consumer access to generic drugs act, HR 1506-FAIR generics act, HOUSE OF REPRESENTATIVES,Securities & Exchange Commission (SEC),SENATE,U.S. Trade Representative (USTR)   80000 0 0 2019-04-15T13:11:36.403000-04:00
2265897 NATIONAL HOME INFUSION ASSOCIATION 530d993c-ee60-4a14-a85e-d103248c07e8 Q1 NATIONAL HOME INFUSION ASSOCIATION 40047365 NATIONAL HOME INFUSION ASSOCIATION 2019 first_quarter PHA FDA MOU Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,White House Office   20000 0 0 2019-04-15T14:24:41.513000-04:00
2266446 CONNECT 4 STRATEGIES, LLC 008e93cb-7be8-473c-a30f-9fd27a7fa3a2 Q1 CONNECT 4 STRATEGIES, LLC 401103720 AKCEA THERAPEUTICS, INC. 2019 first_quarter PHA FDA drug approval issues HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2019-04-15T21:03:09.257000-04:00
2266589 SGR LLC GOVERNMENT RELATIONS AND LOBBYING 6f6ca064-1d35-4a2a-8bf0-50837cc01093 1T SGR LLC GOVERNMENT RELATIONS AND LOBBYING 401103335 LEVIN, PAPANTONIO, THOMAS, MITCHELL, RAFFERTY & PROCTOR, P.A. 2019 first_quarter PHA PhRMA HOUSE OF REPRESENTATIVES     0 1 2019-04-16T09:37:43.437000-04:00
2266652 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 3ea4f8b5-f36e-4747-9dfa-689711ed6b7c Q1 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 29403 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2019 first_quarter PHA Pseudoephedrine -- Potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient and oppose PSE restrictions such as a prescription requirement (no bill number). Mandatory recall authority of the FDA Supporting a process within FDA that ensures clarity and timely outcomes for the FDA, applicants and stakeholders, as well as utilizing existing technologies to further streamline the prescription-to-nonprescription switch application process without changing the existing clear distinction between prescription and nonprescription medicines. Commerce, Dept of (DOC),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE,Treasury, Dept of   159000 0 0 2019-04-16T10:09:15.353000-04:00
2266972 ZHF CONSULTING LLC 12686698-9a17-48ed-88c0-7b4e98b9677a Q1 ZHF CONSULTING LLC 401103689 MEDISCA, INC. 2019 first_quarter PHA Opioid crisis/alternative pain medication/including defense HOUSE OF REPRESENTATIVES,SENATE 22500   0 0 2019-04-16T11:44:35.783000-04:00
2267174 AMERICAN PHARMACISTS ASSOCIATION 0bf954e1-7e54-4ecb-a45c-9403fca00c7d Q1 AMERICAN PHARMACISTS ASSOCIATION 3071 AMERICAN PHARMACISTS ASSOCIATION 2019 first_quarter PHA S. 988 - Improving Transparency and Accuracy in Medicare Part D Drug Spending Act H.R. 789 - To amend title XVIII of the Social Security Act to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. H.R. 803 - This bill prohibits Medicare prescription drug plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. (A "clean claim" is a Medicare claim that is free of defects such as incomplete documentation.) H.R. 1034 - Phair Pricing Act of 2019; To amend title XVIII of the Social Security Act to require pharmacy-negotiated price concessions to be included in negotiated prices at the point-of-sale under part D of the Medicare program H.R. 1035 - Prescription Drug Price Transparency Act H.R. 1959 - Preserving Patient Access to Compounded Medications Act of 2019 HOUSE OF REPRESENTATIVES,SENATE   34000 0 0 2019-04-16T12:37:39.127000-04:00
2267320 WINNING STRATEGIES WASHINGTON 8cdcb891-4aff-4e99-94e4-75af88561e3d Q1 WINNING STRATEGIES WASHINGTON 50796 KALEO 2019 first_quarter PHA Pharmaceutical drug development, including epinephrine for anaphlylaxis; drug access and affordability issues HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2019-04-16T13:28:23.483000-04:00
2267377 ALEXANDER J. BECKLES, L.L.C. 9f6638fd-1db5-4d88-a968-5fe8fdf1c570 Q1 ALEXANDER J. BECKLES, L.L.C. 40038308 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA 2019 first_quarter PHA H.R. 6505 - Medicare Negotiation and Competitive Licensing Act of 2018; Medicare Part D HOUSE OF REPRESENTATIVES 5000   0 0 2019-04-16T13:42:37.730000-04:00
2267882 ICE MILLER STRATEGIES LLC 860476da-925e-4657-9946-23486015120c Q1 ICE MILLER STRATEGIES LLC 316057 LIFESCIENCE LOGISTICS, LLC 2019 first_quarter PHA Issues involving the storage and distribution of pharmaceuticals and medical items. HOUSE OF REPRESENTATIVES,SENATE     0 0 2019-04-16T16:01:26.380000-04:00
2267998 KOUNTOUPES DENHAM CARR & REID, LLC 1d4214f8-8051-4aba-b6e0-5ded05feac95 Q1 KOUNTOUPES DENHAM CARR & REID, LLC 320918 GLENMARK PHARMACEUTICALS, INC., USA 2019 first_quarter PHA General information about the company and the industry. Issues related to affordability and pricing of pharmaceuticals. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2019-04-16T16:51:20.580000-04:00
2268073 MR. VINCENT A. PANVINI a04f55ea-7ec3-4a2b-945d-3672f32241c2 Q1 MR. VINCENT A. PANVINI 401008845 PHRMA 2019 first_quarter PHA Position on Price Controls; Intellectual Property Rights; Patent Protections. HOUSE OF REPRESENTATIVES,SENATE     0 0 2019-04-16T18:13:00.280000-04:00
2268239 ATRIUM HEALTH-FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM 3d7cbab0-4e1d-4f6d-b4c5-11631571ebde Q1 ATRIUM HEALTH-FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM 58534 ATRIUM HEALTH - FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM 2019 first_quarter PHA HR 4392- To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes; Opposition to any provision in any bill to reduce the scope and use of the 340B Drug Discount benefit; HR 4710 340B PAUSE Act Any provision(s) reducing or changing the 340B Drug Discount Program or benefits to hospitals limiting hospital access to the benefit and or improving or updating the program's guidelines. HOUSE OF REPRESENTATIVES,SENATE   13972 0 0 2019-04-17T09:33:36.240000-04:00
2268255 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 17da2406-576d-4041-8c3d-18d86e1471b1 Q1 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 401103605 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 2019 first_quarter PHA Discussed potential solutions for drug shortages, in addition to general education about role of bio/pharmaceutical contract manufacturing organizations and development service providers. HOUSE OF REPRESENTATIVES,SENATE   50000 0 0 2019-04-17T09:39:44.123000-04:00
2268379 MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) 726e6d97-f733-40d8-93bd-3a18ea23aa1a Q1 MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) 24486 INOVIO PHARMACEUTICALS 2019 first_quarter PHA Government Relations Services including developing strategies to achieve legislative goals, inclusion of MERS on list of neglected diseases at FDA Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2019-04-17T10:26:37.173000-04:00
2268606 KOUNTOUPES DENHAM CARR & REID, LLC 440d3e76-260f-4c50-adb6-2b8b9b4c6375 Q1 KOUNTOUPES DENHAM CARR & REID, LLC 320918 BLOOD CANCER UNITED (FORMERLY REPORTED ASTHE LEUKEMIA AND LYMPHOMA SOCIETY) 2019 first_quarter PHA Issues related to the cost of care and protecting patient access to blood cancer treatment. Issues related to specialty drug tiers. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2019-04-17T11:19:54.680000-04:00
2268765 FARRAGUT PARTNERS LLP fa221f00-410d-4f8e-8444-faebed514fa1 Q1 FARRAGUT PARTNERS LLP 401103938 COMMUNITY ONCOLOGY ALLIANCE 2019 first_quarter PHA Issues related to pharmacy benefit managers. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2019-04-17T11:39:45.743000-04:00
2268790 FARRAGUT PARTNERS LLP 0d5637a4-6e9f-4961-bec0-f060dc9664f5 1A FARRAGUT PARTNERS LLP 401103938 COMMUNITY ONCOLOGY ALLIANCE 2019 first_quarter PHA Issues related to pharmacy benefit managers. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2019-04-17T11:42:53.327000-04:00
2268853 MWW GROUP c0dd207a-7588-4e82-af13-f053b609b7ac 1T MWW GROUP 26318 UNITED PHARMACY PARTNERS, INC. (UPPI) 2019 first_quarter PHA Draft legislation regarding High Enriched Uranium (HEU) HOUSE OF REPRESENTATIVES,SENATE     0 1 2019-04-17T11:47:15.297000-04:00
2268876 UPS (UNITED PARCEL SERVICE) c5881722-2b26-4633-9425-3157ca00b039 Q1 UPS (UNITED PARCEL SERVICE) 39223 UPS (UNITED PARCEL SERVICE) 2019 first_quarter PHA -HR 3204 -National license standards for 3PLs Commerce, Dept of (DOC),Congressional Budget Office (CBO),Executive Office of the President (EOP),Federal Aviation Administration (FAA),Government Accountability Office (GAO),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),Transportation, Dept of (DOT),Treasury, Dept of,U.S. Customs & Border Protection,U.S. Trade Representative (USTR)   2070000 0 0 2019-04-17T11:50:24.550000-04:00
2269027 KOUNTOUPES DENHAM CARR & REID, LLC 905cd0f9-1071-4c8e-85e4-8d88b8a0b7a9 Q1 KOUNTOUPES DENHAM CARR & REID, LLC 320918 ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) 2019 first_quarter PHA Policy matters related to generic pharmaceuticals and biosimilars, including H. R. 965 and S.340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019. H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. Changes to the Risk Evaluation and Mitigation Strategies (REMS) program. Reimbursement rate for biosimilars. H. R. 6, SUPPORT for Patients and Communities Act. HOUSE OF REPRESENTATIVES,SENATE,White House Office 60000   0 0 2019-04-17T12:14:16.117000-04:00
2269127 KOUNTOUPES DENHAM CARR & REID, LLC eb042ca3-bc39-4ce4-aef8-df2e94290023 Q1 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2019 first_quarter PHA General issues related to over the counter pharmaceuticals. Issues related to draft legislation addressing the over the counter drug monograph process including H.R.269, the Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2019-04-17T12:30:56.493000-04:00
2269372 BROWN & FORTUNATO, P.C. 919a31cd-7df5-45bb-aafb-e2a92205d77a Q1 BROWN & FORTUNATO, P.C. 401104878 PROMPTCARE COMPANIES, INC. 2019 first_quarter PHA Issues related to Medicare home infusion therapy benefit and other health care issues. Centers For Medicare and Medicaid Services (CMS) 8000   0 0 2019-04-17T13:32:23.767000-04:00
2269446 ISEMAN & ASSOCIATES LLC f8112e29-9c2b-466f-9aee-736b717cd66b Q1 ISEMAN & ASSOCIATES LLC 401103582 TICHENOR VENTURES, LLC 2019 first_quarter PHA Monitoring biotech legislation; prescription drug prices HOUSE OF REPRESENTATIVES,SENATE 12500   0 0 2019-04-17T13:49:00.107000-04:00
2269525 GOVERNMENT COUNSEL, LLC 0c98dc40-0d6a-4b51-8e9d-7c978641d641 Q1 GOVERNMENT COUNSEL, LLC 401105070 HEALTHCARE DISTRIBUTION ALLIANCE 2019 first_quarter PHA General issues related to opioid abuse (implementation of Public Law 115-271) and ARCOS data. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2019-04-17T14:03:26.980000-04:00
2269623 NATIONAL ASSOCIATION OF BENEFITS AND INSURANCE PROFESSIONALS c90dda68-7e87-4b8a-b40d-5161d15aab71 Q1 NATIONAL ASSOCIATION OF BENEFITS AND INSURANCE PROFESSIONALS 26808 NATIONAL ASSOCIATION OF BENEFITS AND INSURANCE PROFESSIONALS 2019 first_quarter PHA HR 938: A bill to amend the Federal Food, Drug, and Cosmetic Act, with respect to eligibility for approval of a subsequent generic drug, to remove the barrier to that approval posed by the 180-day exclusivity period afforded to a first generic applicant that has not yet received final approval, and for other purposes HR 1520: A bill to amend the Public Health Service Act to provide for the publication of a list of licensed biological products, and for other purposes. HR 1503: A bill to amend the Federal Food, Drug, and Cosmetic Act regarding the list under section 505(j)(7) of the Federal Food, Drug, and Cosmetic Act, and for other purposes. HR 1499: A bill prohibit brand name drug manufacturers from compensating generic drug manufacturers to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable product manufacturers to delay entry of biosimilar and interchangeable products, and for other purposes. HR 965: promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products. Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Internal Revenue Service (IRS),Labor, Dept of (DOL),SENATE,Treasury, Dept of,White House Office   330000 0 0 2019-04-17T14:29:07.787000-04:00
2270104 TRAVERE THERAPEUTICS 6eb39afe-b211-459c-84c7-b195dd99c2ae Q1 TRAVERE THERAPEUTICS 401104190 TRAVERE THERAPEUTICS 2019 first_quarter PHA H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   280000 0 0 2019-04-17T15:52:10.077000-04:00
2270412 OREGON HEALTH & SCIENCE UNIVERSITY 167839ae-5a59-49f3-aa3c-3eb43a0a8b75 Q1 OREGON HEALTH & SCIENCE UNIVERSITY 30291 OREGON HEALTH & SCIENCE UNIVERSITY 2019 first_quarter PHA 340b Drug Discount Program for safety net hospitals and Health Resources and Services Administration proposed omnibus guidance. HOUSE OF REPRESENTATIVES,SENATE   80000 0 0 2019-04-17T16:58:56.620000-04:00
2270473 HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) 9aba5f32-1b94-469c-baf0-0734b21c3e11 Q1 HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) 28776 HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA) 2019 first_quarter PHA Opioid Abuse - General issues related to opioid abuse (implementation of Public Law 115-271) Issues related to ARCOS data Importation of Prescription Drugs (HR 447, HR 478, HR 1478, S 61, S 97, S 658, S 844) Implementation of Public Law 113-54 (DSCSA) Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE   301047 0 0 2019-04-17T17:28:19.770000-04:00
2270904 MEHLMAN CONSULTING, INC. 49d3d88c-9c88-42e2-bde8-df901775e3ea Q1 MEHLMAN CONSULTING, INC. 284950 BLUE SHIELD OF CALIFORNIA 2019 first_quarter PHA Prescription drug pricing. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2019-04-18T09:04:09.033000-04:00
2270973 WAXMAN STRATEGIES a0bc050d-b214-4353-9363-fc9419b50869 Q1 WAXMAN STRATEGIES 401103693 340B HEALTH 2019 first_quarter PHA Issues affecting the 340B drug pricing program; Appropriations for 340B program. HOUSE OF REPRESENTATIVES 60000   0 0 2019-04-18T09:11:27.947000-04:00
2271191 FAEGRE BAKER DANIELS CONSULTING da5a4914-5b6a-4126-b0a1-fdc3558257cc Q1 FAEGRE BAKER DANIELS CONSULTING 34158 ALLIANCE FOR SAFE ONLINE PHARMACIES (ASOP) 2019 first_quarter PHA Illicit prescription drug sales online; rouge internet drug sellers; danger of counterfeit medicines Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE 70000   0 0 2019-04-18T09:33:28.340000-04:00
2271225 FAEGRE BAKER DANIELS CONSULTING 9ae8aefa-327e-4ad9-8a44-ab60c6ccbf56 Q1 FAEGRE BAKER DANIELS CONSULTING 34158 NATIONAL ASSOCIATION OF BOARDS OF PHARMACY 2019 first_quarter PHA Pharmacy regulation; Prescription drug monitoring Centers For Disease Control & Prevention (CDC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),SENATE 110000   0 0 2019-04-18T09:37:38.423000-04:00
2271335 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 73a96ff6-f180-46c6-a9c3-cbaab15c5868 Q1 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 NATIONAL HEMOPHILIA FOUNDATION 2019 first_quarter PHA Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing programs. Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 50000   0 0 2019-04-18T10:05:26.900000-04:00
2271403 NATIONAL ASSOCIATION OF CHAIN DRUG STORES f69c47f1-906b-474a-8a0e-fa2e80aabe12 Q1 NATIONAL ASSOCIATION OF CHAIN DRUG STORES 26672 NATIONAL ASSOCIATION OF CHAIN DRUG STORES 2019 first_quarter PHA H.R. 1614 A bill to amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes S. 724 A bill to amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes S.340 CREATES Act of 2019 H.R. 985 FAST Generics Act of 2019 S.640 Phair Pricing Act of 2019 S. 97 Affordable and Safe Prescription Drug Importation Act S. 61 Safe and Affordable Drugs from Canada Act of 2019 H.R. 1034 Phair Pricing Act of 2019 H.R. 965 CREATES Act of 2019 H.R. 1478 Affordable Insulin Act of 2019 H.R. 447 Affordable and Safe Prescription Drug Importation Act HOUSE OF REPRESENTATIVES,SENATE   1080000 0 0 2019-04-18T10:18:51.083000-04:00
2271648 COVINGTON & BURLING LLP 638f11ac-8fb0-4ce7-9bf1-024681966436 Q1 COVINGTON & BURLING LLP 11195 CELGENE CORPORATION 2019 first_quarter PHA Expressing support for changes to the CREATES Act (S. 340) and Fair Access for Safe and timely (FAST) Generics Act (H.R. 985) HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2019-04-18T10:51:18.067000-04:00
2271747 BLUE CROSS AND BLUE SHIELD ASSOCIATION 41114586-d635-4296-8862-557a4ba9c10e Q1 BLUE CROSS AND BLUE SHIELD ASSOCIATION 6358 BLUE CROSS AND BLUE SHIELD ASSOCIATION 2019 first_quarter PHA Opioids (Epidemic, Deterrence, Economic Impact Zones); CREATES Act;Drug Pricing; PBM/Prescription Drug Costs Rx Rebates; Direct-to-Consumer Rx Advertising;Rx Rebates; Biosimilars H.R.1781 - 116th Congress (2019-2020) Payment Commission Data Act of 2019 Sponsor: Rep. Carter, Earl L. "Buddy" [R-GA-1] H.R.938 - 116th Congress (2019-2020) BLOCKING Act of 2019 Sponsor: Rep. Schrader, Kurt [D-OR-5] H.R.1520 - 116th Congress (2019-2020) Purple Book Continuity Act of 2019 Sponsor: Rep. Eshoo, Anna G. [D-CA-18] H.R.1503 - 116th Congress (2019-2020) Orange Book Transparency Act of 2019 Sponsor: Rep. Kelly, Robin L. [D-IL-2] H.R.1499 - 116th Congress (2019-2020) Protecting Consumer Access to Generic Drugs Act of 2019 Sponsor: Rep. Rush, Bobby L. [D-IL-1] H.R.965 - 116th Congress (2019-2020) CREATES Act of 2019 Sponsor: Rep. Cicilline, David N. [D-RI-1] Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Office of Management & Budget (OMB),Office of Personnel Management (OPM),SENATE,Treasury, Dept of,White House Office   1580000 0 0 2019-04-18T11:07:00.487000-04:00
2271902 AMERICAN CONSERVATIVE UNION fcca2bf5-d03a-4dd0-8cd8-915e8dd5c849 Q1 AMERICAN CONSERVATIVE UNION 62712 AMERICAN CONSERVATIVE UNION 2019 first_quarter PHA Administrative rule making on efforts on amending the safe harbor regulation concerning discounts, of prescription pharmaceutical products in Medicare/Medicaid. Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Treasury, Dept of,White House Office   10000 0 0 2019-04-18T11:27:57.317000-04:00
2271992 BALLARD PARTNERS ba37b4bb-686f-4a7e-bf0d-d1efec468164 Q1 BALLARD PARTNERS 401104288 LABORATORY CORPORATIONS OF AMERICA HOLDINGS 2019 first_quarter PHA Clinical Lab Rates Health & Human Services, Dept of (HHS),White House Office 80000   0 0 2019-04-18T11:37:36.183000-04:00
2272178 FTI GOVERNMENT AFFAIRS 434d1915-4852-4073-8a74-c4e566e7aa54 Q1 FTI GOVERNMENT AFFAIRS 401054971 PERRIGO, INC. 2019 first_quarter PHA Repeals a requirement enacted into law as part of the PPACA of 2010 that requires consumers to obtain a prescription in order to utilize their FSA's and HSA's to purchase over-the-counter OTC medicines. FDA's proposed changes to generic drug labeling. "Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018", H.R. 5333. "Over-the-Counter Drug Safety, Innovation, and Reform Act", S. 2315. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2019-04-18T12:04:44.317000-04:00
2272544 ACADEMY OF MANAGED CARE PHARMACY 33a30158-f00c-4a08-b0f2-94561db1fe2b Q1 ACADEMY OF MANAGED CARE PHARMACY 48793 ACADEMY OF MANAGED CARE PHARMACY 2019 first_quarter PHA Communication and correspondence in opposition to S. 657, Drug Price Transparency Act (Braun), support for S. 659, Biologic Patent Transparency Act, support for S. 340/H.R. 965, the CREATES Act, support to changes in 42 C.F.R. Chapter 2, and dissemination of materials on pharmaceutical information exchange (no introduced legislation to date) Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   45000 0 0 2019-04-18T13:05:57.263000-04:00
2272671 HANCE SCARBOROUGH 051fca8e-11a1-46df-801c-4e52908c2aab Q1 HANCE SCARBOROUGH 17443 TITAN PHARMACEUTICALS, INC. 2019 first_quarter PHA Medicare/Medicaid drug coverage, opioid addiction policy. HOUSE OF REPRESENTATIVES,SENATE     0 0 2019-04-18T13:21:36.653000-04:00
2272797 HANCE SCARBOROUGH b42e2dcd-6574-457c-936b-f61e6564f167 Q1 HANCE SCARBOROUGH 17443 ALLIANCE FOR PHARMACY COMPOUNDING 2019 first_quarter PHA Issues related to the regulation of pharmacy compounding. HR 1959 Preserving Patient Access to Compounded Medications Act. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2019-04-18T13:36:18.773000-04:00
2273161 ELI LILLY AND COMPANY e617af2e-9bde-4f81-98ec-ed75ad64c6af Q1 ELI LILLY AND COMPANY 13392 ELI LILLY AND COMPANY 2019 first_quarter PHA Hospital discounts; 340B program Agriculture, Dept of (USDA),Commerce, Dept of (DOC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),U.S. Trade Representative (USTR)   1370000 0 0 2019-04-18T14:40:41.617000-04:00
2273375 AARP 9c3769ff-873c-4a30-bd56-95e1f42202f9 Q1 AARP 1694 AARP 2019 first_quarter PHA H.R. 21, Consolidated Appropriations Act FY 2019, H.R. 648, 2nd Consolidated Appropriations Act FY 2019, H.J.R. 31 Continuing Appropriations for Homeland Security FY 2019, H.J.R. 143, H.R. 695, Short-term Continuing Appropriations Act Resolution FY 2019, Agriculture-Rural Development Appropriations bill (no bill numbers) - lobbied to protect funding for FDA drug processing funding and user fees. Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Securities & Exchange Commission (SEC),SENATE,Transportation, Dept of (DOT)   1840000 0 0 2019-04-18T15:11:03.613000-04:00
2273410 KOUNTOUPES DENHAM CARR & REID, LLC ef5e96dd-235b-4370-beb9-b5448ee52ea8 Q1 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CVS HEALTH 2019 first_quarter PHA General education about the pharmacy benefit manager/pharmacy industry, including S.476, The Creating Transparency to Have Drug Rebates Unlocked (C-THRU)Act. Issues related to Risk Evaluation and Mitigation Strategies (REMS) program, including S.340 and H. R. 965, The CREATES Act. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office 50000   0 0 2019-04-18T15:17:12.010000-04:00
2273486 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION 31fda5d5-1fed-4da1-b0da-c2332741ddce Q1 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION 31348 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION 2019 first_quarter PHA Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks. Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, direct and indirect remuneration (DIR), pharmacy networks, and mail-service pharmacy. Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses. H.R. 803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act. H.R.1034/S.640: Phair Pricing Act of 2019. H.R.1035: Prescription Drug Price Transparency Act. S. 476: C-THRU Act Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Medicare Payment Advisory Commission (MedPAC),Office of Management & Budget (OMB),SENATE   1492460 0 0 2019-04-18T15:30:44.147000-04:00
2273591 ROCK & ASSOCIATES 35b94649-c95c-487c-8ec8-13d375f2176b Q1 ROCK & ASSOCIATES 33545 BRAIDWOOD MANAGEMENT, INC. 2019 first_quarter PHA H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2019-04-18T15:47:28.147000-04:00
2273609 THE LIVINGSTON GROUP, LLC 17a30b10-7d87-4466-aa6e-7f4ce8d74e65 Q1 THE LIVINGSTON GROUP, LLC 49635 RUSH UNIVERSITY MEDICAL CENTER 2019 first_quarter PHA Maintain the 340B program for hospitals Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE 70000   0 0 2019-04-18T15:48:31.567000-04:00
2273679 ROCK & ASSOCIATES 104ecded-3658-49ea-9bf5-7f6e5a8de2dd Q1 ROCK & ASSOCIATES 33545 VETERINARY PHARMACIES OF AMERICA, INC. 2019 first_quarter PHA H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2019-04-18T15:51:44.307000-04:00
2273697 ROCK & ASSOCIATES 7a5f3daf-b46d-421c-baba-7d8a6e9f75c1 Q1 ROCK & ASSOCIATES 33545 WOMEN'S INTERNATIONAL PHARMACY 2019 first_quarter PHA H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2019-04-18T15:54:51.150000-04:00
2273704 ROCK & ASSOCIATES 2b3d4e94-c746-41f2-aff4-019be19c8c60 Q1 ROCK & ASSOCIATES 33545 WELLNESS PHARMACY 2019 first_quarter PHA H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2019-04-18T15:55:54.950000-04:00

Next page

Advanced export

JSON shape: default, array, newline-delimited, object

CSV options:

CREATE TABLE lobbying_activities (
            id INTEGER PRIMARY KEY,
            filing_uuid TEXT NOT NULL,
            filing_type TEXT NOT NULL,
            registrant_name TEXT NOT NULL,
            registrant_id INTEGER,
            client_name TEXT NOT NULL,
            filing_year INTEGER NOT NULL,
            filing_period TEXT NOT NULL,
            issue_code TEXT,
            specific_issues TEXT,
            government_entities TEXT,
            income_amount INTEGER,
            expense_amount INTEGER,
            is_no_activity INTEGER DEFAULT 0,
            is_termination INTEGER DEFAULT 0,
            received_date TEXT,
            CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
                REFERENCES lobbying_filings_raw(filing_uuid)
        );
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);
Powered by Datasette · Queries took 1585.035ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API